DBV Technologies Q2 2026: Cash Burn Accelerates, BLA Submission Delayed to Q3
DBVT sits 75% above its 52-week low of $8.51.
Summary
DBV Technologies posted a $50.4M Q2 net loss, with H1 2026 cash burn nearly doubling year-over-year to $102.6M. The BLA submission for its peanut allergy patch is now expected in Q3 2026, a slight delay. Cash of $174.9M funds operations into Q3 2027.
Key Events · Earnings and Guidance · DBVT
-
Q2 2026 Net Loss Widens
Net loss of $50.4M for Q2 2026, contributing to a $98.0M loss for H1 2026, compared to $69.0M in H1 2025.
-
Cash Burn Accelerates
Net cash used in operating and investing activities surged to $102.6M in H1 2026, up from $54.0M in H1 2025, driven by clinical trials, manufacturing build-up, and commercial readiness.
-
BLA Submission Delayed to Q3 2026
The BLA for VIASKIN Peanut Patch in children 4–7 years is now expected in Q3 2026, a shift from the prior Q2 2026 timeline, due to FDA feedback on data formatting.
-
Cash Runway into Q3 2027
Cash and equivalents of $174.9M as of June 30, 2026, are projected to fund operations into the third quarter of 2027, excluding any new financing or in-licensing.
Analysis · DBVT · Life Sciences
A net loss of $50.4 million in Q2 2026 pushed DBV Technologies' half-year loss to $98.0 million—nearly double the $69.0 million recorded in H1 2025. Cash and equivalents dropped to $174.9 million, which is expected to fund operations into Q3 2027. Meanwhile, the BLA submission for the VIASKIN Peanut Patch has slipped from Q2 to Q3 2026, reflecting ongoing FDA feedback on data formatting. Although the delay is modest, the accelerating cash burn and rising operating expenses highlight the capital-intensive nature of the pre-commercial buildout. The company is investing heavily in manufacturing, medical affairs, and a U.S. commercial infrastructure ahead of a potential launch, with no revenue yet. The runway extends into Q3 2027, but the path to approval and commercialization remains binary and expensive.
At the time of this filing, DBVT was trading at $14.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $937.9M. The 52-week trading range was $8.51 to $26.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.